BRUSSELS—European Union regulators handed down fines totaling €427.7 million ($582.1 million) to French pharmaceutical company Laboratoires Servier SA and five generic drug producers on Wednesday for colluding to delay a cheaper version of a blood-pressure medicine.. The decision is the third and by far the largest set of fines imposed by EU antitrust authorities for so-called pay-for-delay deals in the pharmaceutical industry, in which drug makers are accused of paying generic rivals to delay the introduction of cheaper versions...
  